HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that two abstracts on its lead product candidate BPX-501 have been selected for presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden on June 14-17, 2018.
The presentations will include updated interim survival results from pediatric patients with primary immunodeficiencies (PIDs) and acute myelogenous leukemia (AML) who are undergoing a curative haplo-HSCT with BPX-501.
Oral Presentation Details
Title: Administration of BPX-501 Cells Following Alpha/Beta T-cell and B-cell-Depleted HLA‑Haploidentical HSCT (haplo-HSCT) in Children with Primary Immunodeficiencies Abstract: S871
Session Title: Stem cell transplantation - Clinical II
Date: Saturday, June 16
Time: 4:00 - 4:15 p.m. CEST
Poster Presentation Details
Title: Administration of BPX-501 Cells Following Alpha/Beta T-cell and B-cell-Depleted HLA‑Haploidentical HSCT (haplo-HSCT) in Children with Acute Myelogenous Leukemia Abstract: PS989
Session Title: Acute myeloid leukemia - Clinical
Date: Saturday, June 16
Time: 5:30 – 7:00 p.m. CEST
The BPX-501 clinical presentations at the conference will include updated information beyond that included in the abstracts currently available online on the EHA conference website.
About BPX-501
BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD or other T-cell mediated transplant complications occur. This may enable physicians to more safely perform stem cell transplants by administering BPX-501 engineered T cells to speed immune reconstitution, provide control over viral infections, and enhance graft-versus-leukemic activity while minimizing GvHD side effects.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Forward-Looking Statement
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our BPX-501, CID, CAR T and TCR programs; the effectiveness of BPX-501; its possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success of our clinical trials. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2017 and our report on Form 10-Q for the quarter ended March 31, 2018. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications
Brad Miles
646-513-3125
bmiles@bmccommunications.com
Source: Bellicum Pharmaceuticals